Format

Send to

Choose Destination
Neurology. 2017 Sep 5;89(10):1078-1086. doi: 10.1212/WNL.0000000000004340. Epub 2017 Aug 9.

Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.

Author information

1
From the Department of Neurology (J.-I.B., J.M., D.-Y.K., H.S., J.-S.S., J.-A.L., T.-J.K., W.-J.L., H.S.L., J.-S.J. S.-T.L., K.-H.J., K.-Y.J., S.K.L., K.C.), Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Center for Medical Innovations, Biomedical Research Institute, Seoul National University Hospital; Department of Neurology (J.-I.B.), Kyung Hee University Hospital at Gangdong; Program in Neuroscience (J.-I.B., J.M., H.S., J.-A.L., T.-J.K., W.-J.L., H.S.L., J.-S.J., S.-T.L., K.-H.J., K.-Y.J., S.K.L., K.C.), Seoul National University College of Medicine; Department of Neurology (J.-S.S.), Soonchunhyang University Seoul Hospital; Department of Neurology (J.-A.L.), National Center for Mental Health, an affiliate of the Ministry for Health & Welfare; and Department of Neurology (K.-I.P.), Seoul National University Hospital Healthcare System Gangnam Center, Republic of Korea.
2
From the Department of Neurology (J.-I.B., J.M., D.-Y.K., H.S., J.-S.S., J.-A.L., T.-J.K., W.-J.L., H.S.L., J.-S.J. S.-T.L., K.-H.J., K.-Y.J., S.K.L., K.C.), Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Center for Medical Innovations, Biomedical Research Institute, Seoul National University Hospital; Department of Neurology (J.-I.B.), Kyung Hee University Hospital at Gangdong; Program in Neuroscience (J.-I.B., J.M., H.S., J.-A.L., T.-J.K., W.-J.L., H.S.L., J.-S.J., S.-T.L., K.-H.J., K.-Y.J., S.K.L., K.C.), Seoul National University College of Medicine; Department of Neurology (J.-S.S.), Soonchunhyang University Seoul Hospital; Department of Neurology (J.-A.L.), National Center for Mental Health, an affiliate of the Ministry for Health & Welfare; and Department of Neurology (K.-I.P.), Seoul National University Hospital Healthcare System Gangnam Center, Republic of Korea. stemcell.snu@gmail.com sangkun2923@gmail.com.

Abstract

OBJECTIVE:

To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH).

METHODS:

This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms.

RESULTS:

Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only < midodrine + pyridostigmine < pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients.

CONCLUSIONS:

Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms.

CLINICALTRIALSGOV IDENTIFIER:

NCT02308124.

CLASSIFICATION OF EVIDENCE:

This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months.

PMID:
28794253
DOI:
10.1212/WNL.0000000000004340
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center